{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:03:00Z","timestamp":1790092980187,"version":"4.0.1"},"reference-count":178,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,22]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Circulating tumor DNA (ctDNA) is increasingly investigated in lymphomas because it enables noninvasive molecular profiling, longitudinal assessment of clonal evolution, and quantification of minimal residual disease (MRD), which reflects residual tumor burden and treatment response and serves as a clinically validated prognostic biomarker. The clinical utilities of ctDNA include supporting diagnosis, enabling early detection of relapses, and resolving ambiguous imaging findings. Current approaches for ctDNA assessment in lymphomas include droplet digital polymerase chain reaction, immunoglobulin clonotype sequencing, hybrid-capture next-generation sequencing with unique molecular identifiers or duplex barcoding, and phased sequencing. Establishing ctDNA as a clinical-grade assay requires rigorous quality control and standardization across all technical steps, from blood collection and plasma processing to cell-free DNA extraction, quantification, and analytically validated genotyping and MRD measurement. Large prospective trials and international standardization efforts are underway to define ctDNA-based MRD assessment as a reproducible and clinically actionable tool in lymphoma care. In this review, we outline key preanalytical and analytical workflows for ctDNA assessment in lymphomas and discuss unresolved challenges and future directions in the field.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024015609","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T22:01:10Z","timestamp":1781301670000},"page":"6299-6322","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Analysis of cell-free DNA in lymphomas: from sample collection to genotyping and minimal residual disease monitoring"],"prefix":"10.1182","volume":"10","author":[{"given":"Deborah","family":"Piffaretti","sequence":"first","affiliation":[{"name":"1Laboratory of Experimental Hematology, Institute of Oncology Research, Bellinzona, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Consoli","sequence":"additional","affiliation":[{"name":"2Department of Molecular Biotechnology and Health Sciences, University of Torino, Turin, Italy"},{"name":"3Division of Hematology and Stem Cell Transplant Unit, Azienda Ospedaliera Universitaria Citt\u00e0 della Salute e della Scienza, University of Torino, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Rossi","sequence":"additional","affiliation":[{"name":"1Laboratory of Experimental Hematology, Institute of Oncology Research, Bellinzona, Switzerland"},{"name":"4Clinic of Hematology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland"},{"name":"5Faculty of Biomedical Sciences, Universit\u00e0 della Svizzera Italiana, Lugano, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"issue":"10","key":"2026092211215374200_bib1","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1001\/jamainternmed.2023.3603","article-title":"Assessing the clinical utility of liquid biopsies across 5 potential indications from therapy selection to population screening: a review","volume":"183","author":"Carr","year":"2023","journal-title":"JAMA Intern Med"},{"issue":"3","key":"2026092211215374200_bib2","doi-asserted-by":"crossref","first-page":"e70286","DOI":"10.1002\/cncr.70286","article-title":"Minimal residual disease in solid tumors: clinical applications and future directions","volume":"132","author":"Abdo","year":"2026","journal-title":"Cancer"},{"issue":"1","key":"2026092211215374200_bib3","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41571-024-00967-y","article-title":"Minimal residual disease as a target for liquid biopsy in patients with solid tumours","volume":"22","author":"Pantel","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"2026092211215374200_bib4","doi-asserted-by":"crossref","first-page":"e154941","DOI":"10.1172\/JCI154941","article-title":"Circulating tumor DNA: current challenges for clinical utility","volume":"132","author":"Dang","year":"2022","journal-title":"J Clin Invest"},{"issue":"22","key":"2026092211215374200_bib5","doi-asserted-by":"crossref","first-page":"4530","DOI":"10.1158\/1078-0432.CCR-23-0079","article-title":"Circulating tumor DNA to drive treatment in metastatic colorectal cancer","volume":"29","author":"Patelli","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2026092211215374200_bib6","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1200\/OP-24-00648","article-title":"Cell-free DNA in hematologic malignancies","volume":"20","author":"Schroers-Martin","year":"2024","journal-title":"JCO Oncol Pract"},{"issue":"3","key":"2026092211215374200_bib7","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.pathol.2021.01.004","article-title":"Role of cell-free DNA in haematological malignancies","volume":"53","author":"Lim","year":"2021","journal-title":"Pathology"},{"key":"2026092211215374200_bib8","doi-asserted-by":"crossref","first-page":"1164517","DOI":"10.3389\/fonc.2023.1164517","article-title":"Liquid biopsy in hematological malignancies: current and future applications","volume":"13","author":"Talotta","year":"2023","journal-title":"Front Oncol"},{"issue":"17","key":"2026092211215374200_bib9","doi-asserted-by":"crossref","first-page":"13219","DOI":"10.3390\/ijms241713219","article-title":"Using cfDNA and ctDNA as oncologic markers: a path to clinical validation","volume":"24","author":"Dao","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026092211215374200_bib10","doi-asserted-by":"crossref","first-page":"100087","DOI":"10.1016\/j.bdq.2019.100087","article-title":"The emerging role of cell-free DNA as a molecular marker for cancer management","volume":"17","author":"Bronkhorst","year":"2019","journal-title":"Biomol Detect Quantif"},{"issue":"16","key":"2026092211215374200_bib11","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.3390\/cancers15164022","article-title":"Genetic profiling of cell-free DNA in liquid biopsies: a complementary tool for the diagnosis of B-cell lymphomas and the surveillance of measurable residual disease","volume":"15","author":"Figaredo","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"34","key":"2026092211215374200_bib12","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1200\/JCO-25-01534","article-title":"Remission assessment by circulating tumor DNA in large B-cell lymphoma","volume":"43","author":"Roschewski","year":"2025","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026092211215374200_bib13","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/bjh.19458","article-title":"Liquid biopsy for molecular characterization of diffuse large B-cell lymphoma and early assessment of minimal residual disease","volume":"205","author":"Alcoceba","year":"2024","journal-title":"Br J Haematol"},{"issue":"10","key":"2026092211215374200_bib14","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1182\/blood.2024027355","article-title":"A comprehensive genetic study of classic Hodgkin lymphoma using circulating tumor DNA","volume":"146","author":"Pirosa","year":"2025","journal-title":"Blood"},{"issue":"6","key":"2026092211215374200_bib15","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1182\/blood.2023022020","article-title":"Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNA","volume":"143","author":"Heger","year":"2024","journal-title":"Blood"},{"issue":"7996","key":"2026092211215374200_bib16","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/s41586-023-06903-x","article-title":"Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling","volume":"625","author":"Alig","year":"2024","journal-title":"Nature"},{"issue":"4","key":"2026092211215374200_bib17","doi-asserted-by":"crossref","first-page":"648","DOI":"10.3324\/haematol.2018.206177","article-title":"Liquid biopsy in lymphoma","volume":"104","author":"Rossi","year":"2019","journal-title":"Haematologica"},{"issue":"7943","key":"2026092211215374200_bib18","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/s41586-022-05580-6","article-title":"A DNA methylation atlas of normal human cell types","volume":"613","author":"Loyfer","year":"2023","journal-title":"Nature"},{"issue":"11","key":"2026092211215374200_bib19","doi-asserted-by":"crossref","first-page":"E1317","DOI":"10.1073\/pnas.1500076112","article-title":"Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients","volume":"112","author":"Jiang","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"2026092211215374200_bib20","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/nrclinonc.2017.14","article-title":"Integrating liquid biopsies into the management of cancer","volume":"14","author":"Siravegna","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"2026092211215374200_bib21","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1086\/302205","article-title":"Rapid clearance of fetal DNA from maternal plasma","volume":"64","author":"Lo","year":"1999","journal-title":"Am J Hum Genet"},{"issue":"20","key":"2026092211215374200_bib22","doi-asserted-by":"crossref","first-page":"5207","DOI":"10.1182\/bloodadvances.2025016752","article-title":"Monitoring ctDNA in aggressive B-cell lymphoma: a prospective correlative study of ctDNA kinetics and PET-CT metrics","volume":"9","author":"Vimalathas","year":"2025","journal-title":"Blood Adv"},{"issue":"23","key":"2026092211215374200_bib23","doi-asserted-by":"crossref","first-page":"6130","DOI":"10.1182\/bloodadvances.2025016332","article-title":"Early clearance of circulating tumor DNA and association with odronextamab response in relapsed\/refractory FL and DLBCL","volume":"9","author":"Arnason","year":"2025","journal-title":"Blood Adv"},{"issue":"3","key":"2026092211215374200_bib24","first-page":"646","article-title":"Free DNA in the serum of cancer patients and the effect of therapy","volume":"37","author":"Leon","year":"1977","journal-title":"Cancer Res"},{"issue":"224","key":"2026092211215374200_bib25","doi-asserted-by":"crossref","first-page":"224ra24","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of circulating tumor DNA in early- and late-stage human malignancies","volume":"6","author":"Bettegowda","year":"2014","journal-title":"Sci Transl Med"},{"issue":"7","key":"2026092211215374200_bib26","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1182\/bloodadvances.2024014136","article-title":"Molecular clustering on ctDNA improves the prognostic stratification of patients with DLBCL compared with ctDNA levels","volume":"9","author":"Moia","year":"2025","journal-title":"Blood Adv"},{"issue":"3","key":"2026092211215374200_bib27","doi-asserted-by":"crossref","first-page":"e008450","DOI":"10.1136\/jitc-2023-008450","article-title":"Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy","volume":"12","author":"Zou","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"16","key":"2026092211215374200_bib28","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1200\/JCO.2017.76.8671","article-title":"Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists joint review","volume":"36","author":"Merker","year":"2018","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026092211215374200_bib29","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/nrc.2017.7","article-title":"Liquid biopsies come of age: towards implementation of circulating tumour DNA","volume":"17","author":"Wan","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"2026092211215374200_bib30","doi-asserted-by":"crossref","first-page":"e006013","DOI":"10.1136\/jitc-2022-006013","article-title":"Cell-free DNA approaches for cancer early detection and interception","volume":"11","author":"Medina","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026092211215374200_bib31","doi-asserted-by":"crossref","first-page":"639233","DOI":"10.3389\/fcell.2021.639233","article-title":"Cell-free DNA: hope and potential application in cancer","volume":"9","author":"Yan","year":"2021","journal-title":"Front Cell Dev Biol"},{"issue":"2","key":"2026092211215374200_bib32","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41576-018-0071-5","article-title":"Current and future perspectives of liquid biopsies in genomics-driven oncology","volume":"20","author":"Heitzer","year":"2019","journal-title":"Nat Rev Genet"},{"issue":"1-2","key":"2026092211215374200_bib33","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.cell.2015.11.050","article-title":"Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin","volume":"164","author":"Snyder","year":"2016","journal-title":"Cell"},{"issue":"8","key":"2026092211215374200_bib34","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.tig.2021.04.005","article-title":"The nexus of cfDNA and nuclease biology","volume":"37","author":"Han","year":"2021","journal-title":"Trends Genet"},{"issue":"7","key":"2026092211215374200_bib35","doi-asserted-by":"crossref","first-page":"e00699","DOI":"10.1016\/j.heliyon.2018.e00699","article-title":"Factors that influence quality and yield of circulating-free DNA: a systematic review of the methodology literature","volume":"4","author":"Trigg","year":"2018","journal-title":"Heliyon"},{"issue":"40","key":"2026092211215374200_bib36","doi-asserted-by":"crossref","first-page":"E5503","DOI":"10.1073\/pnas.1508736112","article-title":"Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments","volume":"112","author":"Sun","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"18","key":"2026092211215374200_bib37","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.clinbiochem.2016.09.009","article-title":"Cell-free DNA in maternal plasma and serum: a comparison of quantity, quality and tissue origin using genomic and epigenomic approaches","volume":"49","author":"Wong","year":"2016","journal-title":"Clin Biochem"},{"issue":"3","key":"2026092211215374200_bib38","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/ijc.33217","article-title":"Liquid biopsies: potential and challenges","volume":"148","author":"Heidrich","year":"2021","journal-title":"Int J Cancer"},{"issue":"689","key":"2026092211215374200_bib39","doi-asserted-by":"crossref","first-page":"eabm8729","DOI":"10.1126\/scitranslmed.abm8729","article-title":"Clonal hematopoiesis detection in patients with cancer using cell-free DNA sequencing","volume":"15","author":"Fairchild","year":"2023","journal-title":"Sci Transl Med"},{"issue":"4","key":"2026092211215374200_bib40","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1001\/jamaoncol.2024.6144","article-title":"Circulating tumor DNA as measurable residual disease in aggressive B-cell lymphoma: a narrative review","volume":"11","author":"Roschewski","year":"2025","journal-title":"JAMA Oncol"},{"issue":"28","key":"2026092211215374200_bib41","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1200\/JCO.2018.78.5246","article-title":"Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma","volume":"36","author":"Kurtz","year":"2018","journal-title":"J Clin Oncol"},{"issue":"26","key":"2026092211215374200_bib42","doi-asserted-by":"crossref","first-page":"6499","DOI":"10.1007\/s00216-014-7835-3","article-title":"Towards standardisation of cell-free DNA measurement in plasma: controls for extraction efficiency, fragment size bias and quantification","volume":"406","author":"Devonshire","year":"2014","journal-title":"Anal Bioanal Chem"},{"issue":"1","key":"2026092211215374200_bib43","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41375-025-02759-4","article-title":"ctDNA dynamics demonstrates rapid treatment response to tafasitamab + R-CHOP +\/- lenalidomide and predicts outcome in diffuse large B-cell lymphoma: results from the phase 1b First-MIND study","volume":"40","author":"Khouja","year":"2026","journal-title":"Leukemia"},{"issue":"1","key":"2026092211215374200_bib44","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41375-025-02787-0","article-title":"Noninvasive genotyping and early disease dynamics demonstrate the efficacy of ibrutinib in combination with immunochemotherapy in patients with mantle cell lymphoma treated in the TRIANGLE trial","volume":"40","author":"Khouja","year":"2026","journal-title":"Leukemia"},{"issue":"5","key":"2026092211215374200_bib45","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1200\/JCO-25-01587","article-title":"Phased variant-supported circulating tumor DNA as a prognostic biomarker after first-line treatment in large B-cell lymphoma: findings from the DIRECT Study","volume":"44","author":"Krupka","year":"2026","journal-title":"J Clin Oncol"},{"key":"2026092211215374200_bib46","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.cca.2013.05.022","article-title":"Circulating cell free DNA: preanalytical considerations","volume":"424","author":"El Messaoudi","year":"2013","journal-title":"Clin Chim Acta"},{"issue":"12","key":"2026092211215374200_bib47","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/s41587-021-00981-w","article-title":"Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA","volume":"39","author":"Kurtz","year":"2021","journal-title":"Nat Biotechnol"},{"issue":"5","key":"2026092211215374200_bib48","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1200\/JCO-25-01712","article-title":"Prospective validation of circulating tumor DNA measurable residual disease after first-line therapy in large B-cell lymphoma","volume":"44","author":"Wang","year":"2026","journal-title":"J Clin Oncol"},{"key":"2026092211215374200_bib49","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1196\/annals.1368.042","article-title":"The importance of careful blood processing in isolation of cell-free DNA","volume":"1075","author":"Page","year":"2006","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"2026092211215374200_bib50","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/hon.3087","article-title":"Circulating cell-free DNA for target quantification in hematologic malignancies: validation of a protocol to overcome pre-analytical biases","volume":"41","author":"Soscia","year":"2023","journal-title":"Hematol Oncol"},{"key":"2026092211215374200_bib51","doi-asserted-by":"crossref","first-page":"5585148","DOI":"10.1155\/2021\/5585148","article-title":"Optimization of preanalytical variables for cfDNA processing and detection of ctDNA in archival plasma samples","volume":"2021","author":"Nesic","year":"2021","journal-title":"Biomed Res Int"},{"issue":"1","key":"2026092211215374200_bib52","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1093\/clinchem\/hvad194","article-title":"Critical factors in the analytical work flow of circulating tumor DNA-based molecular profiling","volume":"70","author":"van der Leest","year":"2024","journal-title":"Clin Chem"},{"key":"2026092211215374200_bib53","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/978-1-4939-8876-1_19","article-title":"Methods for measuring ctDNA in lymphomas","volume":"1881","author":"Rossi","year":"2019","journal-title":"Methods Mol Biol"},{"issue":"3","key":"2026092211215374200_bib54","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/BF02982039","article-title":"Specimen collection, storage, and transmission to the laboratory for hematological tests","volume":"75","author":"Tatsumi","year":"2002","journal-title":"Int J Hematol"},{"issue":"8","key":"2026092211215374200_bib55","doi-asserted-by":"crossref","first-page":"4252","DOI":"10.3390\/ijms25084252","article-title":"Error-corrected deep targeted sequencing of circulating cell-free DNA from colorectal cancer patients for sensitive detection of circulating tumor DNA","volume":"25","author":"Frydendahl","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2026092211215374200_bib56","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/s41467-017-00965-y","article-title":"Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors","volume":"8","author":"Adalsteinsson","year":"2017","journal-title":"Nat Commun"},{"issue":"1","key":"2026092211215374200_bib57","doi-asserted-by":"crossref","first-page":"12564","DOI":"10.1038\/s41598-020-69432-x","article-title":"Evaluating the quantity, quality and size distribution of cell-free DNA by multiplex droplet digital PCR","volume":"10","author":"Alcaide","year":"2020","journal-title":"Sci Rep"},{"issue":"12","key":"2026092211215374200_bib58","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.jmoldx.2023.09.004","article-title":"Recommendations for cell-free DNA assay validations: a joint consensus recommendation of the Association for Molecular Pathology and College of American Pathologists","volume":"25","author":"Lockwood","year":"2023","journal-title":"J Mol Diagn"},{"issue":"14","key":"2026092211215374200_bib59","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1182\/blood-2016-05-719641","article-title":"Diffuse large B-cell lymphoma genotyping on the liquid biopsy","volume":"129","author":"Rossi","year":"2017","journal-title":"Blood"},{"issue":"24","key":"2026092211215374200_bib60","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1182\/blood-2015-03-635169","article-title":"Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing","volume":"125","author":"Kurtz","year":"2015","journal-title":"Blood"},{"issue":"22","key":"2026092211215374200_bib61","doi-asserted-by":"crossref","first-page":"4674","DOI":"10.1182\/bloodadvances.2021004528","article-title":"Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumab","volume":"5","author":"Bruscaggin","year":"2021","journal-title":"Blood Adv"},{"issue":"1","key":"2026092211215374200_bib62","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s12885-021-09160-1","article-title":"Whole genome deep sequencing analysis of cell-free DNA in samples with low tumour content","volume":"22","author":"Ganesamoorthy","year":"2022","journal-title":"BMC Cancer"},{"key":"2026092211215374200_bib63","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-4939-8973-7_1","volume-title":"Cell-free DNA as Diagnostic Markers: Methods and Protocols","author":"Ranucci","year":"2019"},{"issue":"18","key":"2026092211215374200_bib64","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1056\/NEJMra1706174","article-title":"Application of cell-free DNA analysis to cancer treatment","volume":"379","author":"Corcoran","year":"2018","journal-title":"N Engl J Med"},{"issue":"466","key":"2026092211215374200_bib65","doi-asserted-by":"crossref","first-page":"eaat4921","DOI":"10.1126\/scitranslmed.aat4921","article-title":"Enhanced detection of circulating tumor DNA by fragment size analysis","volume":"10","author":"Mouliere","year":"2018","journal-title":"Sci Transl Med"},{"issue":"1","key":"2026092211215374200_bib66","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/s41598-022-27216-5","article-title":"Evaluation of automated techniques for extraction of circulating cell-free DNA for implementation in standardized high-throughput workflows","volume":"13","author":"Lehle","year":"2023","journal-title":"Sci Rep"},{"issue":"1","key":"2026092211215374200_bib67","doi-asserted-by":"crossref","first-page":"12479","DOI":"10.1038\/s41598-025-95226-0","article-title":"A rapid and high-yield method for nucleic acid extraction","volume":"15","author":"Vutukuru","year":"2025","journal-title":"Sci Rep"},{"issue":"1","key":"2026092211215374200_bib68","doi-asserted-by":"crossref","first-page":"19364","DOI":"10.1038\/s41598-025-03508-4","article-title":"Evaluation of automatic cell free DNA extraction metrics using different blood collection tubes","volume":"15","author":"Andersson","year":"2025","journal-title":"Sci Rep"},{"issue":"4","key":"2026092211215374200_bib69","doi-asserted-by":"crossref","first-page":"e0266889","DOI":"10.1371\/journal.pone.0266889","article-title":"Direct comparison of circulating tumor DNA sequencing assays with targeted large gene panels","volume":"17","author":"Yu","year":"2022","journal-title":"PLoS One"},{"issue":"1","key":"2026092211215374200_bib70","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jmoldx.2023.10.001","article-title":"Analytical performance evaluation of a 523-gene circulating tumor DNA assay for next-generation sequencing-based comprehensive tumor profiling in liquid biopsy samples","volume":"26","author":"Harter","year":"2024","journal-title":"J Mol Diagn"},{"issue":"1","key":"2026092211215374200_bib71","doi-asserted-by":"crossref","first-page":"4973","DOI":"10.1038\/s41598-024-54361-w","article-title":"Analytical evaluation of circulating tumor DNA sequencing assays","volume":"14","author":"Li","year":"2024","journal-title":"Sci Rep"},{"issue":"3","key":"2026092211215374200_bib72","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jmoldx.2017.01.011","article-title":"Guidelines for validation of next-generation sequencing-based oncology panels: a joint consensus recommendation of the Association for Molecular Pathology and College of American Pathologists","volume":"19","author":"Jennings","year":"2017","journal-title":"J Mol Diagn"},{"issue":"12","key":"2026092211215374200_bib73","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1373\/clinchem.2018.291278","article-title":"Applying standard clinical chemistry assay validation to droplet digital PCR quantitative liquid biopsy testing","volume":"64","author":"Milosevic","year":"2018","journal-title":"Clin Chem"},{"key":"2026092211215374200_bib74","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/978-1-0716-2950-5_5","article-title":"MYD88 L265P mutation detection by ddPCR: recommendations for screening and minimal residual disease monitoring: ddPCR for highly sensitive detection of MYD88 L265P mutation","volume":"2621","author":"Drandi","year":"2023","journal-title":"Methods Mol Biol"},{"issue":"10","key":"2026092211215374200_bib75","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/nmeth.2633","article-title":"Absolute quantification by droplet digital PCR versus analog real-time PCR","volume":"10","author":"Hindson","year":"2013","journal-title":"Nat Methods"},{"key":"2026092211215374200_bib76","doi-asserted-by":"crossref","first-page":"105679","DOI":"10.1016\/j.humpath.2024.105679","article-title":"Clinical use of circulating tumor DNA analysis in patients with lymphoma","volume":"156","author":"Bisig","year":"2025","journal-title":"Hum Pathol"},{"issue":"1","key":"2026092211215374200_bib77","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13045-025-01673-7","article-title":"Circulating tumor DNA in lymphoma: technologies and applications","volume":"18","author":"Fu","year":"2025","journal-title":"J Hematol Oncol"},{"key":"2026092211215374200_bib78","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/978-1-0716-4188-0_8","article-title":"MRD detection in B-cell non-Hodgkin lymphomas using Ig gene rearrangements and chromosomal translocations as targets for real-time quantitative PCR and ddPCR","volume":"2865","author":"Pott","year":"2025","journal-title":"Methods Mol Biol"},{"key":"2026092211215374200_bib79","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/978-1-0716-2115-8_7","article-title":"cfDNA-based NGS IG analysis in lymphoma","volume":"2453","author":"Pott","year":"2022","journal-title":"Methods Mol Biol"},{"issue":"6","key":"2026092211215374200_bib80","doi-asserted-by":"crossref","first-page":"596","DOI":"10.3390\/ph14060596","article-title":"cfDNA sequencing: technological approaches and bioinformatic issues","volume":"14","author":"Bohers","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"2026092211215374200_bib81","doi-asserted-by":"crossref","first-page":"1407003","DOI":"10.3389\/fonc.2024.1407003","article-title":"Tumor-informed ctDNA assessment as a valuable prognostic and predictive biomarker in diffuse large B-cell lymphoma","volume":"14","author":"Narkhede","year":"2024","journal-title":"Front Oncol"},{"issue":"1","key":"2026092211215374200_bib82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/19336918.2024.2395807","article-title":"Liquid biopsy: paving a new avenue for cancer research","volume":"18","author":"Kurma","year":"2024","journal-title":"Cell Adh Migr"},{"issue":"4","key":"2026092211215374200_bib83","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41587-022-01222-4","article-title":"Inferring gene expression from cell-free DNA fragmentation profiles","volume":"40","author":"Esfahani","year":"2022","journal-title":"Nat Biotechnol"},{"key":"2026092211215374200_bib84","doi-asserted-by":"crossref","first-page":"101237","DOI":"10.1016\/j.blre.2024.101237","article-title":"Clinical applications of circulating tumor DNA in hematological malignancies: from past to the future","volume":"68","author":"Li","year":"2024","journal-title":"Blood Rev"},{"issue":"6","key":"2026092211215374200_bib85","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1158\/1078-0432.CCR-13-2482","article-title":"Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA","volume":"20","author":"Oxnard","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2026092211215374200_bib86","doi-asserted-by":"crossref","first-page":"e0229063","DOI":"10.1371\/journal.pone.0229063","article-title":"The stochastic nature of errors in next-generation sequencing of circulating cell-free DNA","volume":"15","author":"Nix","year":"2020","journal-title":"PLoS One"},{"issue":"5","key":"2026092211215374200_bib87","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nbt.3520","article-title":"Integrated digital error suppression for improved detection of circulating tumor DNA","volume":"34","author":"Newman","year":"2016","journal-title":"Nat Biotechnol"},{"issue":"17","key":"2026092211215374200_bib88","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.1182\/bloodadvances.2025015791","article-title":"Circulating tumor DNA determinants of response and outcome in relapsed\/refractory mantle cell lymphoma","volume":"9","author":"Meriranta","year":"2025","journal-title":"Blood Adv"},{"issue":"9","key":"2026092211215374200_bib89","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1080\/10428194.2019.1573998","article-title":"Analysis of circulating tumor DNA by targeted ultra-deep sequencing across various non-Hodgkin lymphoma subtypes","volume":"60","author":"Shin","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"2026092211215374200_bib90","doi-asserted-by":"crossref","first-page":"11815","DOI":"10.1038\/ncomms11815","article-title":"Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients","volume":"7","author":"Chabon","year":"2016","journal-title":"Nat Commun"},{"issue":"25","key":"2026092211215374200_bib91","doi-asserted-by":"crossref","first-page":"7083","DOI":"10.1016\/j.cell.2025.10.020","article-title":"Longitudinal ultrasensitive ctDNA monitoring for high-resolution lung cancer risk prediction","volume":"188","author":"Black","year":"2025","journal-title":"Cell"},{"key":"2026092211215374200_bib92","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/978-1-0716-4188-0_21","article-title":"Detection of circulating tumor DNA in lymphoma patients","volume":"2865","author":"Bruscaggin","year":"2025","journal-title":"Methods Mol Biol"},{"issue":"364","key":"2026092211215374200_bib93","doi-asserted-by":"crossref","first-page":"364ra155","DOI":"10.1126\/scitranslmed.aai8545","article-title":"Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA","volume":"8","author":"Scherer","year":"2016","journal-title":"Sci Transl Med"},{"key":"2026092211215374200_bib94","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/978-1-4939-9151-8_20","article-title":"Ultrasensitive detection of circulating tumor DNA in lymphoma via targeted hybridization capture and deep sequencing of barcoded libraries","volume":"1956","author":"Alcaide","year":"2019","journal-title":"Methods Mol Biol"},{"issue":"3","key":"2026092211215374200_bib95","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/s41416-021-01696-0","article-title":"Cell-free DNA analysis in current cancer clinical trials: a review","volume":"126","author":"Cisneros-Villanueva","year":"2022","journal-title":"Br J Cancer"},{"issue":"1","key":"2026092211215374200_bib96","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1158\/2643-3230.BCD-21-0029","article-title":"Circulating tumor DNA in lymphoma: principles and future directions","volume":"3","author":"Roschewski","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"4","key":"2026092211215374200_bib97","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1038\/s41436-018-0278-z","article-title":"Standard operating procedure for somatic variant refinement of sequencing data with paired tumor and normal samples","volume":"21","author":"Barnell","year":"2019","journal-title":"Genet Med"},{"issue":"8","key":"2026092211215374200_bib98","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1182\/bloodadvances.2022009461","article-title":"Audit of B-cell cancer genes","volume":"9","author":"Coyle","year":"2025","journal-title":"Blood Adv"},{"issue":"34","key":"2026092211215374200_bib99","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1200\/JCO-25-01932","article-title":"Assessing remission in diffuse large B-cell lymphoma: will minimal residual disease add value to positron emission tomography?","volume":"43","author":"Rossi","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026092211215374200_bib100","doi-asserted-by":"crossref","first-page":"329","DOI":"10.18632\/oncotarget.28719","article-title":"Analytical validation of a circulating tumor DNA assay using PhasED-seq technology for detecting residual disease in B-cell malignancies","volume":"16","author":"Klimova","year":"2025","journal-title":"Oncotarget"},{"issue":"1","key":"2026092211215374200_bib101","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1038\/s41467-021-24109-5","article-title":"Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS","volume":"12","author":"Rose Brannon","year":"2021","journal-title":"Nat Commun"},{"issue":"9","key":"2026092211215374200_bib102","doi-asserted-by":"crossref","first-page":"e0237802","DOI":"10.1371\/journal.pone.0237802","article-title":"Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin","volume":"15","author":"Woodhouse","year":"2020","journal-title":"PLoS One"},{"issue":"6","key":"2026092211215374200_bib103","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/ejh.14191","article-title":"Noninvasive minimal residual disease assessment in relapsed\/refractory large B-cell lymphoma using digital droplet PCR","volume":"112","author":"Heger","year":"2024","journal-title":"Eur J Haematol"},{"key":"2026092211215374200_bib104","doi-asserted-by":"crossref","first-page":"923809","DOI":"10.3389\/fonc.2022.923809","article-title":"Reliability of cell-free DNA and targeted NGS in predicting chromosomal abnormalities of patients with myeloid neoplasms","volume":"12","author":"Ip","year":"2022","journal-title":"Front Oncol"},{"issue":"4","key":"2026092211215374200_bib105","doi-asserted-by":"crossref","first-page":"e0267389","DOI":"10.1371\/journal.pone.0267389","article-title":"Analytical and clinical validation of an amplicon-based next generation sequencing assay for ultrasensitive detection of circulating tumor DNA","volume":"17","author":"Poh","year":"2022","journal-title":"PLoS One"},{"issue":"9","key":"2026092211215374200_bib106","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1038\/s41587-021-00857-z","article-title":"Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology","volume":"39","author":"Deveson","year":"2021","journal-title":"Nat Biotechnol"},{"issue":"5","key":"2026092211215374200_bib107","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jmoldx.2019.05.003","article-title":"Optimized (pre) analytical conditions and workflow for droplet digital PCR analysis of cell-free DNA from patients with suspected lung carcinoma","volume":"21","author":"de Kock","year":"2019","journal-title":"J Mol Diagn"},{"key":"2026092211215374200_bib108","doi-asserted-by":"crossref","first-page":"1176698","DOI":"10.3389\/fonc.2023.1176698","article-title":"Whole-genome informed circulating tumor DNA analysis by multiplex digital PCR for disease monitoring in B-cell lymphomas: a proof-of-concept study","volume":"13","author":"Haider","year":"2023","journal-title":"Front Oncol"},{"issue":"11","key":"2026092211215374200_bib109","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.3390\/cancers17111734","article-title":"Clinical implication of sequential circulating tumor DNA assessments for the treatment of diffuse large B-cell lymphoma","volume":"17","author":"Song","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"4","key":"2026092211215374200_bib110","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1080\/10428194.2021.2010060","article-title":"Circulating tumor DNA in primary mediastinal large B-cell lymphoma versus classical Hodgkin lymphoma: a retrospective study","volume":"63","author":"Camus","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2026092211215374200_bib111","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3324\/haematol.2019.237719","article-title":"Targeted genotyping of circulating tumor DNA for classical Hodgkin lymphoma monitoring: a prospective study","volume":"106","author":"Camus","year":"2021","journal-title":"Haematologica"},{"issue":"8","key":"2026092211215374200_bib112","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-018-0111-6","article-title":"Non-invasive monitoring of diffuse large B-cell lymphoma by cell-free DNA high-throughput targeted sequencing: analysis of a prospective cohort","volume":"8","author":"Bohers","year":"2018","journal-title":"Blood Cancer J"},{"issue":"6","key":"2026092211215374200_bib113","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.3324\/haematol.2017.186528","article-title":"Highly sensitive MYD88(L265P) mutation detection by droplet digital polymerase chain reaction in Waldenstr\u00f6m macroglobulinemia","volume":"103","author":"Drandi","year":"2018","journal-title":"Haematologica"},{"issue":"9","key":"2026092211215374200_bib114","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.3324\/haematol.2016.145102","article-title":"Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma","volume":"101","author":"Camus","year":"2016","journal-title":"Haematologica"},{"issue":"9","key":"2026092211215374200_bib115","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1373\/clinchem.2016.255315","article-title":"Multiplex droplet digital PCR quantification of recurrent somatic mutations in diffuse large B-cell and follicular lymphoma","volume":"62","author":"Alcaide","year":"2016","journal-title":"Clin Chem"},{"issue":"1","key":"2026092211215374200_bib116","first-page":"vdaf274","article-title":"Treatment initiation by positive liquid biopsy alone in primary central nervous system lymphoma: a retrospective analysis of a multi-institutional study","volume":"8","author":"Mitobe","year":"2026","journal-title":"Neurooncol Adv"},{"issue":"16","key":"2026092211215374200_bib117","doi-asserted-by":"crossref","first-page":"4608","DOI":"10.1182\/bloodadvances.2022009426","article-title":"Circulating tumor DNA adds specificity to PET after axicabtagene ciloleucel in large B-cell lymphoma","volume":"7","author":"Dean","year":"2023","journal-title":"Blood Adv"},{"issue":"7","key":"2026092211215374200_bib118","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.3324\/haematol.2024.286331","article-title":"Molecular measurable residual disease by immunoglobulin gene rearrangements on circulating tumor DNA predicts outcome in diffuse large B-cell lymphoma","volume":"110","author":"Soscia","year":"2025","journal-title":"Haematologica"},{"issue":"20","key":"2026092211215374200_bib119","first-page":"4198","article-title":"Next-generation sequencing-based monitoring of circulating tumor DNA reveals clonotypic heterogeneity in untreated PTCL","volume":"5","author":"Miljkovic","year":"2021","journal-title":"Blood Adv"},{"issue":"27","key":"2026092211215374200_bib120","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1200\/JCO.21.00377","article-title":"Monitoring of circulating tumor DNA improves early relapse detection after axicabtagene ciloleucel infusion in large B-cell lymphoma: results of a prospective multi-institutional trial","volume":"39","author":"Frank","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"2026092211215374200_bib121","doi-asserted-by":"crossref","first-page":"oyaf016","DOI":"10.1093\/oncolo\/oyaf016","article-title":"Prognostic relevance of immunoglobulin heavy chain rearrangement and immunoglobulin kappa light chain rearrangement in patients with diffuse large B cell lymphoma","volume":"30","author":"Wang","year":"2025","journal-title":"Oncologist"},{"issue":"23","key":"2026092211215374200_bib122","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1056\/NEJMoa2401532","article-title":"Combination targeted therapy in relapsed diffuse large B-cell lymphoma","volume":"390","author":"Melani","year":"2024","journal-title":"N Engl J Med"},{"issue":"12","key":"2026092211215374200_bib123","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1080\/10428194.2022.2103808","article-title":"Prognostic value of minimal residual disease among patients with classical Hodgkin lymphoma undergoing autologous stem cell transplantation","volume":"63","author":"Taranto","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"2026092211215374200_bib124","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/bloodadvances.2021006397","article-title":"Circulating tumor DNA predicts therapeutic outcome in mantle cell lymphoma","volume":"6","author":"Lakhotia","year":"2022","journal-title":"Blood Adv"},{"issue":"11","key":"2026092211215374200_bib125","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1182\/bloodadvances.2020001637","article-title":"Liquid biopsy in extranodal NK\/T-cell lymphoma: a prospective analysis of cell-free DNA genotyping and monitoring","volume":"5","author":"Qi","year":"2021","journal-title":"Blood Adv"},{"issue":"5","key":"2026092211215374200_bib126","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1111\/ijlh.13498","article-title":"Circulating tumor DNA by high-throughput sequencing of T cell receptor monitored treatment response and predicted treatment failure in T cell lymphomas","volume":"43","author":"Zhang","year":"2021","journal-title":"Int J Lab Hematol"},{"issue":"4","key":"2026092211215374200_bib127","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1182\/bloodadvances.2025017760","article-title":"MRD-driven initial therapy of acalabrutinib and lenalidomide plus rituximab or obinutuzumab for mantle cell lymphoma","volume":"10","author":"Ruan","year":"2026","journal-title":"Blood Adv"},{"issue":"8","key":"2026092211215374200_bib128","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1182\/blood.2024027727","article-title":"Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment","volume":"146","author":"Claudel","year":"2025","journal-title":"Blood"},{"issue":"38","key":"2026092211215374200_bib129","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1080\/14796694.2024.2402209","article-title":"The clinical utility of plasma circulating tumor DNA in the diagnosis and disease surveillance in non-diffuse large B-cell non-Hodgkin lymphomas","volume":"20","author":"Zhang","year":"2024","journal-title":"Future Oncol"},{"issue":"3","key":"2026092211215374200_bib130","doi-asserted-by":"crossref","first-page":"920","DOI":"10.4143\/crt.2023.869","article-title":"Feasibility of circulating tumor DNA analysis in patients with follicular lymphoma","volume":"56","author":"Yoon","year":"2024","journal-title":"Cancer Res Treat"},{"issue":"3","key":"2026092211215374200_bib131","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/s41375-022-01803-x","article-title":"Real-life disease monitoring in follicular lymphoma patients using liquid biopsy ultra-deep sequencing and PET\/CT","volume":"37","author":"Jim\u00e9nez-Ubieto","year":"2023","journal-title":"Leukemia"},{"issue":"35","key":"2026092211215374200_bib132","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1200\/JCO.23.01867","article-title":"Circulating tumor DNA sequencing for biologic classification and individualized risk stratification in patients with Hodgkin lymphoma","volume":"42","author":"Heger","year":"2024","journal-title":"J Clin Oncol"},{"issue":"12","key":"2026092211215374200_bib133","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1182\/blood.2021012852","article-title":"Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma","volume":"139","author":"Meriranta","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2026092211215374200_bib134","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1186\/s12916-022-02562-3","article-title":"Clinical implications of circulating tumor DNA in predicting the outcome of diffuse large B cell lymphoma patients receiving first-line therapy","volume":"20","author":"Li","year":"2022","journal-title":"BMC Med"},{"issue":"6","key":"2026092211215374200_bib135","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1182\/bloodadvances.2021006415","article-title":"Risk profiling of patients with relapsed\/refractory diffuse large B-cell lymphoma by measuring circulating tumor DNA","volume":"6","author":"Herrera","year":"2022","journal-title":"Blood Adv"},{"issue":"10","key":"2026092211215374200_bib136","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.medj.2021.09.002","article-title":"In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkin's lymphoma and facilitates ultrasensitive residual disease detection","volume":"2","author":"Sobesky","year":"2021","journal-title":"Med"},{"issue":"1","key":"2026092211215374200_bib137","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1186\/s12916-025-04418-y","article-title":"Zanubrutinib, lenalidomide and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as initial treatment in non-germinal center B-cell diffuse large B-cell lymphoma: a multi-center phase 2 study by Jiangsu Cooperative Lymphoma Group (JCLG)","volume":"23","author":"Xia","year":"2025","journal-title":"BMC Med"},{"issue":"1","key":"2026092211215374200_bib138","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1186\/s12964-025-02438-y","article-title":"Clinical implications of ctDNA-based minimal residual disease detection in newly diagnosed peripheral T-cell lymphoma: a single-center cohort study","volume":"23","author":"Liang","year":"2025","journal-title":"Cell Commun Signal"},{"issue":"21","key":"2026092211215374200_bib139","doi-asserted-by":"crossref","first-page":"5539","DOI":"10.1182\/bloodadvances.2024015788","article-title":"Measurable residual disease detection after CAR-T may predict response in patients with large B-cell lymphoma","volume":"9","author":"Krasnow","year":"2025","journal-title":"Blood Adv"},{"issue":"5","key":"2026092211215374200_bib140","doi-asserted-by":"crossref","first-page":"e70139","DOI":"10.1002\/hem3.70139","article-title":"Biomarker-adapted treatment in high-risk large B-cell lymphoma","volume":"9","author":"Lepp\u00e4","year":"2025","journal-title":"Hemasphere"},{"issue":"1","key":"2026092211215374200_bib141","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ccell.2022.12.005","article-title":"Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas","volume":"41","author":"Sworder","year":"2023","journal-title":"Cancer Cell"},{"issue":"4","key":"2026092211215374200_bib142","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1200\/JCO.22.00597","article-title":"Smart start: rituximab, lenalidomide, and ibrutinib in patients with newly diagnosed large B-cell lymphoma","volume":"41","author":"Westin","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026092211215374200_bib143","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41375-019-0541-6","article-title":"Genotyping circulating tumor DNA of pediatric Hodgkin lymphoma","volume":"34","author":"Desch","year":"2020","journal-title":"Leukemia"},{"issue":"22","key":"2026092211215374200_bib144","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1182\/blood-2017-11-812073","article-title":"Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma","volume":"131","author":"Spina","year":"2018","journal-title":"Blood"},{"issue":"2","key":"2026092211215374200_bib145","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1182\/blood-2016-02-699520","article-title":"Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma","volume":"128","author":"Assouline","year":"2016","journal-title":"Blood"},{"issue":"5","key":"2026092211215374200_bib146","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1038\/s41591-026-04291-z","article-title":"Liquid biopsy for the diagnosis of EBV-positive Burkitt\u2019s lymphoma in endemic areas","volume":"32","author":"Chamba","year":"2026","journal-title":"Nat Med"},{"issue":"1","key":"2026092211215374200_bib147","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s12916-026-04756-5","article-title":"Dual-utility ctDNA in diffuse large B-cell lymphoma: integrated genotyping unveils minimal residual disease dynamics and subtype-specific clonal evolution","volume":"24","author":"Liang","year":"2026","journal-title":"BMC Med"},{"issue":"1","key":"2026092211215374200_bib148","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13023-026-04226-4","article-title":"Breaking diagnostic and therapeutic barriers in intravascular large B-cell lymphoma: a 13-year real-world study from China","volume":"21","author":"Wang","year":"2026","journal-title":"Orphanet J Rare Dis"},{"key":"2026092211215374200_bib149","doi-asserted-by":"crossref","first-page":"218249","DOI":"10.1016\/j.canlet.2026.218249","article-title":"Baseline tumor-informed circulating tumor DNA concentration predicts early chemoimmunotherapy failure in diffuse large B-cell lymphoma","volume":"640","author":"Shi","year":"2026","journal-title":"Cancer Lett"},{"key":"2026092211215374200_bib150","doi-asserted-by":"crossref","first-page":"218297","DOI":"10.1016\/j.canlet.2026.218297","article-title":"Corrigendum to \"Baseline tumor-informed circulating tumor DNA concentration predicts early chemoimmunotherapy failure diffuse large B-cell lymphoma\" [Cancer Lett. 640 (2026) 218249]","volume":"641","author":"Shi","year":"2026","journal-title":"Cancer Lett"},{"issue":"3","key":"2026092211215374200_bib151","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1111\/bjh.70296","article-title":"Dynamics of circulating tumour DNA in relapsed\/refractory diffuse large B-cell lymphoma patients","volume":"208","author":"Zhong","year":"2026","journal-title":"Br J Haematol"},{"issue":"14","key":"2026092211215374200_bib152","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1080\/10428194.2025.2556961","article-title":"Genetic analysis of cell-free DNA in follicular lymphoma in comparison with tissue-derived DNA","volume":"66","author":"Hori","year":"2025","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"2026092211215374200_bib153","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1038\/s41416-025-03217-9","article-title":"Circulating tumor DNA from blood and cerebrospinal fluid in DLBCL: simultaneous evaluation of mutations, IG rearrangement, and IG clonality","volume":"133","author":"Zhang","year":"2025","journal-title":"Br J Cancer"},{"issue":"5","key":"2026092211215374200_bib154","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1111\/bjh.70128","article-title":"Circulating tumour DNA as a predictor of survival of patients with diffuse large B-cell lymphoma in a daily practice","volume":"207","author":"Vodicka","year":"2025","journal-title":"Br J Haematol"},{"issue":"9","key":"2026092211215374200_bib155","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1200\/JCO.22.00826","article-title":"Circulating tumor DNA profiling for detection, risk stratification, and classification of brain lymphomas","volume":"41","author":"Mutter","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026092211215374200_bib156","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1158\/1078-0432.CCR-22-1654","article-title":"Monitoring of circulating tumor DNA predicts response to treatment and early progression in follicular lymphoma: results of a prospective pilot study","volume":"29","author":"Fern\u00e1ndez-Miranda","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2026092211215374200_bib157","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1038\/s41375-025-02688-2","article-title":"Integration of [(18)F]FDG-PET radiomics with liquid biopsy improves outcome prediction in newly diagnosed diffuse large B-cell lymphoma","volume":"39","author":"Dondolin","year":"2025","journal-title":"Leukemia"},{"issue":"21","key":"2026092211215374200_bib158","first-page":"2576","article-title":"Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma","volume":"141","author":"Lynch","year":"2023","journal-title":"Blood"},{"issue":"11","key":"2026092211215374200_bib159","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1182\/bloodadvances.2022009145","article-title":"Polatuzumab vedotin with infusional chemotherapy for untreated aggressive B-cell non-Hodgkin lymphomas","volume":"7","author":"Lynch","year":"2023","journal-title":"Blood Adv"},{"issue":"22","key":"2026092211215374200_bib160","doi-asserted-by":"crossref","first-page":"5855","DOI":"10.1182\/bloodadvances.2024013277","article-title":"Magrolimab plus rituximab in relapsed\/refractory indolent non-Hodgkin lymphoma: 3-year follow-up of a phase 1\/2 trial","volume":"8","author":"Mehta","year":"2024","journal-title":"Blood Adv"},{"issue":"11","key":"2026092211215374200_bib161","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1080\/10428194.2021.1938027","article-title":"A phase 1\/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed\/refractory B-cell malignancies","volume":"62","author":"Collins","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"2026092211215374200_bib162","doi-asserted-by":"crossref","first-page":"102651","DOI":"10.1016\/j.xcrm.2026.102651","article-title":"Integrative CSF profiling identifies disease-specific immune responses in leptomeningeal disease","volume":"7","author":"Nieto","year":"2026","journal-title":"Cell Rep Med"},{"issue":"1","key":"2026092211215374200_bib163","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41408-026-01450-w","article-title":"Penpulimab combined with rituximab, high-dose methotrexate, and cytarabine (Pen-RMA) in newly diagnosed primary central nervous system lymphoma (PCNSL): a phase 2 trial","volume":"16","author":"Shen","year":"2026","journal-title":"Blood Cancer J"},{"issue":"1","key":"2026092211215374200_bib164","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1227\/neu.0000000000003835","article-title":"Multi-institutional assessment of circulating cell-free DNA in cerebrospinal fluid facilitates central nervous system lymphoma diagnosis and treatment initiation","volume":"99","author":"Prager","year":"2025","journal-title":"Neurosurgery"},{"issue":"9","key":"2026092211215374200_bib165","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.3324\/haematol.2021.279908","article-title":"A pilot study of the use of dynamic analysis of cell-free DNA from aqueous humor and vitreous fluid for the diagnosis and treatment monitoring of vitreoretinal lymphomas","volume":"107","author":"Wang","year":"2022","journal-title":"Haematologica"},{"issue":"14","key":"2026092211215374200_bib166","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1167\/iovs.64.14.27","article-title":"Next-generation sequencing of vitreoretinal lymphoma by vitreous liquid biopsy: diagnostic potential and genotype\/phenotype correlation","volume":"64","author":"Kwak","year":"2023","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"9","key":"2026092211215374200_bib167","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1200\/JOP.19.00691","article-title":"Potential of circulating tumor DNA for the management of patients with lymphoma","volume":"16","author":"Huet","year":"2020","journal-title":"JCO Oncol Pract"},{"issue":"1","key":"2026092211215374200_bib168","doi-asserted-by":"crossref","first-page":"22815","DOI":"10.1038\/s41598-021-02362-4","article-title":"Incorporation of next-generation sequencing in clinical practice using solid and liquid biopsy for patients with non-Hodgkin's lymphoma","volume":"11","author":"Bastos-Oreiro","year":"2021","journal-title":"Sci Rep"},{"issue":"6","key":"2026092211215374200_bib169","doi-asserted-by":"crossref","first-page":"e241","DOI":"10.3324\/haematol.2017.178830","article-title":"Liquid biopsy for the identification of intravascular large B-cell lymphoma","volume":"103","author":"Suehara","year":"2018","journal-title":"Haematologica"},{"issue":"1","key":"2026092211215374200_bib170","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41591-022-02113-6","article-title":"Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome","volume":"29","author":"Parry","year":"2023","journal-title":"Nat Med"},{"issue":"27","key":"2026092211215374200_bib171","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"11","key":"2026092211215374200_bib172","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1016\/j.ejrad.2016.08.011","article-title":"Proportion of false-positive lesions at interim and end-of-treatment FDG-PET in lymphoma as determined by histology: systematic review and meta-analysis","volume":"85","author":"Adams","year":"2016","journal-title":"Eur J Radiol"},{"issue":"5","key":"2026092211215374200_bib173","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1470-2045(15)70106-3","article-title":"Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study","volume":"16","author":"Roschewski","year":"2015","journal-title":"Lancet Oncol"},{"issue":"11","key":"2026092211215374200_bib174","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.6004\/jnccn.2023.0057","article-title":"NCCN Guidelines\u00ae insights: B-cell lymphomas, version 6.2023","volume":"21","author":"Zelenetz","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"2026092211215374200_bib175","doi-asserted-by":"crossref","first-page":"18425","DOI":"10.1038\/srep18425","article-title":"Clinical utility of circulating tumor DNA for molecular assessment in pancreatic cancer","volume":"5","author":"Takai","year":"2015","journal-title":"Sci Rep"},{"key":"2026092211215374200_bib176","doi-asserted-by":"crossref","first-page":"926405","DOI":"10.3389\/fped.2022.926405","article-title":"Clinical implementation of plasma cell-free circulating tumor DNA quantification by digital droplet PCR for the monitoring of Ewing sarcoma in children and adolescents","volume":"10","author":"Seidel","year":"2022","journal-title":"Front Pediatr"},{"key":"2026092211215374200_bib177","author":"Stathis","year":"17-21  2025"},{"issue":"4","key":"2026092211215374200_bib178","doi-asserted-by":"crossref","first-page":"485","DOI":"10.5858\/arpa.2020-0457-OA","article-title":"Assessment of clonotypic rearrangements and minimal residual disease in lymphoid malignancies","volume":"146","author":"Hussaini","year":"2022","journal-title":"Arch Pathol Lab Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/18\/6299\/2589862\/blooda_adv-2024-015609-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/18\/6299\/2589862\/blooda_adv-2024-015609-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:22:19Z","timestamp":1790090539000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/18\/6299\/569115\/Analysis-of-cell-free-DNA-in-lymphomas-from-sample"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":178,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2026,9,22]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024015609","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9,22]]},"published":{"date-parts":[[2026,9,22]]}}}